Government Report
Prescription Drugs: VA Paid About Half as Much as Medicare Part D for Selected Drugs in 2017
U.S. Government Accountability Office, GAO-21-111 · December 2020
Comparing prices for 399 matched brand-name and generic drugs, GAO found the VA paid on average 54% less per unit than Medicare Part D in 2017, even after accounting for Part D rebates and discounts.
Cited in: Before the Counter, Prescription Drugs guide
Read the source →
Government Report
Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs
Federal Trade Commission, Interim Staff Report · July 2024
The FTC found the three largest PBMs — CVS Caremark, Express Scripts, and OptumRx — managed 79% of U.S. prescription drug claims in 2023, up from 70% in 2016, each owned by the same corporate family as a major health insurer.
Cited in: Before the Counter, Prescription Drugs guide
Read the source →
Peer-Reviewed Study
Assessment of Spending in Medicare Part D If Medication Prices From the VA Were Used
Venker, Stephenson & Gellad · JAMA Internal Medicine, 2019
This research letter found Medicare Part D spent $32.5 billion on the top 50 oral drugs in 2016; at VA prices, the same drugs would have cost $18.0 billion — a $14.4 billion gap.
Cited in: Before the Counter, Prescription Drugs guide
Read the source →
Research Report
International Prescription Drug Price Comparisons: Estimates Using 2022 Data
RAND Corporation, Report RRA788-3 · February 2024
RAND found U.S. brand-name drug prices ran 3.22 times those of 33 comparison countries, even after accounting for estimated manufacturer rebates.
Cited in: Before the Counter, Prescription Drugs guide
Read the source →
Peer-Reviewed Study
Contribution of NIH Funding to New Drug Approvals 2010–2016
Cleary, Beierlein, Khanuja, McNamee & Ledley · Proceedings of the National Academy of Sciences, 2018
NIH-funded research was linked to every one of the 210 new drugs the FDA approved between 2010 and 2016, backed by more than $100 billion in NIH project funding over that period.
Cited in: Before the Counter, Prescription Drugs guide, Beyond Reform
Read the source →
Government Report
Additional Information About Drug Price Negotiation and CBO's Simulation Model of Drug Development
Congressional Budget Office · December 21, 2023
CBO estimated that over the next 30 years, 13 fewer new drugs of roughly 1,300 expected will reach the market as a result of Medicare's new negotiating authority — about a 1% reduction.
Cited in: Before the Counter, Prescription Drugs guide
Read the source →
Government Report
Estimated Budgetary Effects of H.R. 5376, the Inflation Reduction Act of 2022
Congressional Budget Office · August 3, 2022
CBO's official cost estimate projected roughly $101.8 billion in Medicare savings from 2022–2031 from the IRA's drug-negotiation provision — the basis for the commonly cited "$102 billion" figure.
Cited in: Before the Counter, Prescription Drugs guide
Read the source →
Peer-Reviewed Study · Author's Own Research
Cost-Effectiveness of Prospective and Continuous Parenteral Antibiotic Control
Coleman, Rodondi, Kaubisch, Granzella & O'Hanley · The American Journal of Medicine, 1991
Robert Coleman's own published research on VA antibiotic stewardship found prospective review of IV antibiotic orders cut antibiotic costs by about a third with no increase in mortality — the pilot that became the basis of a national Medicare/Medicaid stewardship requirement in 2019.
Cited in: Before the Counter
Read the source →